Can antinuclear antibodies (ANA) and other autoantibodies be positive in patients with diffuse large B‑cell lymphoma (DLBCL)?

Can ANA and Other Autoantibodies Be Positive in DLBCL?

Yes, antinuclear antibodies (ANA) and other autoantibodies are frequently positive in patients with diffuse large B-cell lymphoma (DLBCL), occurring in approximately 30-35% of cases—significantly higher than the 6.5-7.5% prevalence seen in healthy controls. 1, 2

Prevalence and Clinical Significance

ANA Positivity in DLBCL

• ANA is detected in 30.5-31.5% of DLBCL patients compared to only 6.5-7.5% of healthy controls, representing a statistically significant difference 1, 2
• The most recent and highest quality evidence demonstrates that ANA positivity is associated with an increased risk of developing DLBCL (OR: 1.83,95% CI: 1.15-2.91), with 19.7% of DLBCL cases testing ANA-positive versus 12.2% of controls 3
• ANA titers in DLBCL are typically low (1:100) with diverse fluorescence patterns 2
• Up to 25% of apparently healthy individuals can test ANA-positive by indirect immunofluorescence, so context is critical 4

Other Autoantibodies in DLBCL

• Anti-extractable nuclear antigen (anti-ENA) or anti-dsDNA antibodies are associated with increased DLBCL risk (OR: 2.93,95% CI: 1.18-7.28), particularly for DLBCL (OR: 3.51,95% CI: 1.02-12.0) 3
• Anti-citrullinated protein antibodies (ACPA) occur significantly more frequently in DLBCL patients (3.5%) versus healthy controls (0.8%), though at much lower concentrations than in rheumatoid arthritis 5
• Rheumatoid factor (RF) is found in 56.7% of NHL patients, with significantly higher mean levels in DLBCL compared to non-DLBCL subtypes 6
• Other autoantibodies detected include anti-ssDNA (10.7%), p-ANCA (6.7%), anti-Scl-70 (2.7%), and anti-Jo-1 (2%) 6

Key Clinical Distinctions

Not Indicative of Autoimmune Disease

• The majority of DLBCL patients with positive ANA do not develop autoimmune diseases, suggesting these antibodies represent a tumor-related immune response rather than true autoimmunity 1
• Autoantibodies in DLBCL may represent an effective immune response to the tumor rather than pathologic autoimmunity 1

Prognostic Implications

• ANA-positive DLBCL patients demonstrate better survival rates (P < 0.05), suggesting ANA may be a favorable stage-independent prognostic factor 1
• Lower lactate dehydrogenase (LDH) levels are significantly associated with ANA positivity in lymphoma patients 2
• ACPA positivity does not correlate with established DLBCL prognostic parameters or overall survival 5
• No significant correlation exists between ANA expression and Ann Arbor clinical stages of DLBCL 1

Clinical Pitfalls and Caveats

Testing Interpretation

• Indirect immunofluorescence assay (IIFA) on HEp-2 cells remains the reference method for ANA detection, though it requires substantial technical expertise 4
• The term "ANA" is outdated and encompasses antibodies to various cellular compartments including nuclear, cytoplasmic, and membrane components 4
• Autoantibody detection in DLBCL helps determine diagnosis and prognosis but has no independent diagnostic value 2

Patient-Specific Factors

• Male DLBCL patients show significantly higher ACPA positivity (4.4% versus 0% in females; OR 1.046, CI 1.014-1.079) 5
• Newly diagnosed DLBCL cases demonstrate significantly higher mean levels of anti-Scl-70, anti-Jo-1, and RF compared to patients with active disease or in follow-up 6
• ACPA positivity is significantly associated with simultaneous RF-IgM seropositivity in DLBCL 5

Clinical Management Implications

• Routine screening for hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV is required in DLBCL workup, but autoantibody screening is not part of standard diagnostic guidelines 4, 7
• Long-term follow-up is needed in NHL patients with high autoantibody levels to monitor for potential autoimmune disease development 6
• The presence of autoantibodies does not alter standard DLBCL treatment approaches with R-CHOP or Pola-R-CHP regimens 7